TrialAlimentary pharmacology & therapeutics2020

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.

Remo Panaccione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.